Industry Experts

Lorelei Stoica is Executive Director, Nonclinical Gene Therapy Research at Ultragenyx Pharmaceutical, leading execution of nonclinical program and platform research to continually optimize and invest in Ultragenyx’s gene therapy programs. Lorelei has contributed to the development of eight rare disease gene therapy programs, including four currently in clinical trials, for CNS, liver and muscle therapeutic areas. Lorelei earned a PhD from the University of Massachusetts, Worcester, studying AAV-delivered microRNAs for the treatment of ALS with Dr Miguel Sena-Esteves.